

Review

Moving towards Personalized Medicine—The Broad Use of Aptamers for Targeted Theranostic

André P. Sousa ^{1,2,3,4,†} , Ana C. Rocha ^{1,2,3,4,†} , Cátia Almeida ^{1,2,3,4,†} , Mariana C. C. G. Carneiro ^{5,6,†} , Patrick P. Pais ^{1,2,†} , Rejane Viana ^{3,†} , Rúben Fernandes ^{1,2,3,7} , Pedro Barata ^{1,2,3} , Álvaro Gestoso ^{1,2} , Susana Ramalho ^{1,2,3,8,9} , Daniela Martins-Mendes ^{1,2,3,7} , Pilar Baylina ^{1,2,3,8,9}  and Ana Cláudia Pereira ^{1,2,3,7,*} 

- ¹ HE-FP—Hospital Fernando Pessoa, CECLIN—Center of Clinical Studies, 4420-096 Gondomar, Portugal; andre.mp.sousa2@hotmail.com (A.P.S.); anacmr13@hotmail.com (A.C.R.); c.rafaela.f.almeida@gmail.com (C.A.); patrickjspais@hotmail.com (P.P.P.); ruben.fernandes@ufp.edu.pt (R.F.); pedro.barata@gmail.com (P.B.); agestoso@ufp.edu.pt (Á.G.); srramalho@gmail.com (S.R.); danielamm@ufp.edu.pt (D.M.-M.); pilarbaylina@ess.ipp.pt (P.B.)
 - ² FP-I3ID—Instituto de Investigação, Inovação e Desenvolvimento, FP-BHS—Biomedical and Health Sciences Research Unit, FFP—Fundação Fernando Pessoa, 4249-004 Porto, Portugal
 - ³ I3S—Instituto de Investigação e Inovação em Saúde, 4200-135 Porto, Portugal; rejaneviananutri@gmail.com
 - ⁴ FMUP, Faculdade de Medicina da Universidade do Porto, 4200-135 Porto, Portugal
 - ⁵ BioMark Sensor Research/ISEP, School of Engineering, Polytechnic Institute, 4249-015 Porto, Portugal; mariana.ccg@gmail.com
 - ⁶ CEB—Centre of Biological Engineering, Minho University, 4710-057 Braga, Portugal
 - ⁷ FCS—Faculty of Health Sciences, Fernando Pessoa University, 4249-004 Porto, Portugal
 - ⁸ ESS—School of Health, IPP—Polytechnic Institute of Porto, 4200-072 Porto, Portugal
 - ⁹ TBIO—Center for Translational Health and Medical Biotechnology Research, IPP—Polytechnic Institute of Porto, 4200-072 Porto, Portugal
- * Correspondence: anacpereira@ufp.edu.pt
† These authors are contributed equally to this work.



Citation: Sousa, A.P.; Rocha, A.C.; Almeida, C.; Carneiro, M.C.C.G.; Pais, P.P.; Viana, R.; Fernandes, R.; Barata, P.; Gestoso, Á.; Ramalho, S.; et al. Moving towards Personalized Medicine—The Broad Use of Aptamers for Targeted Theranostic. *Appl. Sci.* **2023**, *13*, 11933. <https://doi.org/10.3390/app132111933>

Academic Editor: Giuliana Muzio

Received: 22 September 2023

Revised: 22 October 2023

Accepted: 24 October 2023

Published: 31 October 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Aptamers are short, single-stranded oligonucleotides synthesized in vitro from a randomized oligonucleotide library against a specific target. These molecules are capable of binding to a wide range of biological targets with high specificity and affinity. They present great advantages over antibodies with potential applications in research, diagnosis, and therapeutics. Specifically for tumors with late-stage identification and poor prognosis, like pancreatic cancer, the study of novel aptamers holds tremendous potential for cancer diagnosis and treatment. Along with cancer treatment, aptamers have also shown high potential in regulating the immune response and modulating several critical steps of signaling cascades, such as in immune checkpoints. In the context of microbiota and infection, aptamers are being studied to identify microbes and their metabolites. This assessment has the potential to improve the detection and management of infectious diseases while assisting us in better understanding health risks and treatment outcomes by tracking changes in the microbiota. In this review, the potential of aptamers is explored regarding their applications in cancer, immune, and microbiota therapy.

Keywords: aptamer; cancer; immune response; microbiota; SELEX; therapeutic

1. Introduction

Aptamers are short synthetic single-stranded ribonucleic acid (ssRNA) or desoxyribonucleic acid (ssDNA) oligonucleotides, selected through an in vitro method called Systematic Evolution of Ligands by Exponential enrichment (SELEX) [1,2]. They can display high specificity and affinity to a broad spectrum of target molecules, from ions or small molecules to proteins, viruses, bacteria/pathogens, cells, and tissues.

The SELEX process was developed in 1990, simultaneously by two independent groups, Tuerk and Gold [3] and Ellington and Szostak [4], with the goal of isolating

RNA sequences that would specifically recognize target molecules. Since then, many improvements have been made in this procedure to increase its selectivity and shorten the selection process [5]. Aptamers possess a vast field of applications, including diagnosis, therapy and drug delivery systems, food safety, and environment monitoring [1,2,6].

The conventional SELEX involves subsequent cycles of incubation, binding, partitioning, and amplification (Figure 1). It usually starts with a synthetic pool of ssDNA or RNA oligonucleotides called the primary library, which can comprise up to 10^{15} different sequences. This initial pool is incubated with the target molecule (in a free or immobilized form), under specific conditions of incubation. Unbound or weakly bounded sequences are eluted (partitioning) from the target and the target-bound sequences are then retrieved and amplified by PCR or RT-PCR, for DNA or RNA libraries, respectively. The process is repeated for several rounds (between four and 20), with increasingly stringent conditions, in order to obtain a final pool with low heterogeneity and high affinity of sequences is achieved. The enriched oligonucleotides obtained are finally sequenced and their binding affinities to the target are assessed to find the best sequence [1,2].




Figure 1. SELEX usually starts with the incubation of the target molecule and a primary library composed of ssRNA/ssDNA oligonucleotides under specific conditions. Unbound sequences are eluted, and target-bound sequences are amplified by PCR or RT-PCR. These selected sequences are used in subsequent SELEX rounds until the population achieves the required affinity. The final product is sequenced and the affinity of aptamer–target complex is characterized.

The affinity of aptamer–target complex can be characterized by label-free or label-based strategies, through the calculation of dissociation constant (K_d), conformational changes, kinetics, and thermodynamics [7].

Aptamers can exhibit high affinity and low K_d (usually in pico- to nanomolar range) [2], with a similar or even superior target binding affinity than antibodies. In fact, they are often mentioned as chemical antibodies and offer several inherent advantages, as they can be produced over a wide range of targets, display low toxicity and immunogenicity, low molecular weight, good solubility and tissue permeability, high tolerance to environmental conditions (temperature, pH), conformational flexibility, easy modification and conjugation with other molecules, as well as an economical and reproducible synthesis, avoiding animals' dependency for production. Once an aptamer is selected and characterized, it can be produced at a large scale, at low cost, and with low batch inter variability [1,2]. Therefore, numerous aptamers have been selected and applied for cancer, immune, and microbiota research.

In this review, the use of aptamers in research was assessed, especially in the area of cancer, immune activation, and microbiota.

2. Cancer Therapeutics

Aptamers can be applied as therapeutic agents acting mostly as antagonists, binding to the target, and blocking its function, but they can also be applied as agonists, stimulating the targets' function [8–10]. As therapeutic agents, the features of aptamers potentiate their utilization on drug delivery systems for human disease treatment [9,11], as they are capable of transporting a variety of therapeutic agents as small molecules, peptides, or toxins [11].

However, in vivo applications of aptamers actually possess some issues. As an example, the conformation of the target during in vitro selection could be different to the conformation under in vivo conditions, affecting its ability in binding. Also, they have short half-life in vivo due to nuclease sensitivity and fast renal filtration [9,10,12,13].

Nowadays, cancer remains one of the deadliest diseases, with a limited number of reliable biomarkers, as well as reduced specificity, affecting healthy tissues. Examples such as chemotherapy or antagonism, like DNA damage repair drugs, can induce modification in the microenvironment, which can lead to an opposite effect, triggering invasion and/or tumor metastases [6].

In view with this, more efficient, specific, and refined therapies are being studied, targeting different hallmarks of the cancer. One of the most promising is the use of oligonucleotide aptamers, which can bind to specific membrane receptors to start the intended action, having already shown solid results against tumor growth and metastatic capacity, as well as modulating the tumor microenvironment to become more susceptible and easier to treat. This methodology also allows combination with other molecules, such as antibodies, which can enhance and potentiate the response. In fact, studies have shown higher biocompatibility and more refined targeting toward the tumor site, also reducing the possibility of developing resistance to treatment [6].

There are several aptamers being tested in different cancer types, as presented in Table 1, as well as the target and their application (diagnostic, therapy, or both).

Table 1. Main aptamers used in different cancer sites, their targets and applications.

Cancer Site	Aptamer	Target	Application			References
			Diagnostic	Therapy	Theranostic	
Breast	HeA2-3	HER2		X		[14]
	PNDA-3	Periostin		X		[15]
	apMNK2F	MNK1		X		[16]
	apMNK3R			X		[17]
	ex-50.T	Exosomes		X		[18]
	2'-Fluoropyrimidines-RNA	Photothermal therapy in triple-negative phenotype		X		[19]
	AS1411	Nucleolin		X		[20]
Colorectal	YJ-1	CEA		X		[21]
		Death receptor 5		X		[21]
	apPDGF-BB	PDGF-BB		X		[22]
	apPD-1	PD-1		X		[23]
	NOX-A12	CXCL12		X		[24]
Lung	aptPD-L1	Tumor microenvironment (induce IFN γ -inducible; promote T cell)		X		[25]
	AP-74 M-545	Galectin-1		X		[26]
	TBA353	TBA		X		[27]
	TBA535			X		[27]
	RA16	NSCLC cells			X	[28]
Liver	AS1411	Nucleolin		X		[29]
	AS1411 modified	Galectin-14		X		[30]
	CL-4RNV616	EGFR		X		[31]
Renal	SW-4	Caveole-mediated endocytosis process		X		[32]
	SW-4b			X		[32]
	AS1411	Nucleolin		X (PCS II)		[33]

Table 1. Cont.

Cancer Site	Aptamer	Target	Application			References
			Diagnostic	Therapy	Theranostic	
Prostate	Apt63	APT5B		X		[34]
	A9g			X		[35]
	PSMA-specific RNA aptamer	PSMA		X		[36]
	AGRO100	Nucleolin		X (PCS I)		[37]
	CG3	PCA3			X	[38]
Glioblastoma	AS1411	Nucleolin		X		[39]
	shRNA/PEI-PEG-APT/DOX conjugates	PSMA positive cells			X	[40]
Oral	40L	CD133		X		[41]
	A40s			X		[41]
Cervical	Anti-HPSE1	Heparanase		X		[42]
Bladder	A2	E6 and E7 oncogenes		X		[43]
Gastric	alncRNA	TFs		X		[44]
Leukemia	Trimeric	ErbB-2/HER2		X		[45]
Hodkins lymphoma	AS1411	Nucleolin		X		[46]
	ap β -arrestin2	β -arrestin2		X		[47]
	ssRNA MLL-1	MLL-1		X		[48]
Myeloma	CD-RNA aptamer + HAuNS	CD30	X			[49]
Skin	NOX-A12	CXCL12		X		[17]
Pancreas	F3B	MMP-9	X			[50]
	E07	EGFR		X		[51]
	P19	C/EBP α + saRNA		X		[52]
	P1	hTfR protein		X		[52]
	TfR aptamer-C/EBP α -saRNA conjugates			X		[53]
	XQ-2d-His-SH2 CM-(Arg)9 conjugate	PDAC stroma		X		[54]
	SQ-2	ALPP L-2			X	[55,56]
	Apt1	CD24/44/133 and EpCAM			X	[57]
	Apt146				X	[57]
	X-aptamer	Thy-1			X	[58]
Aptacoy	TfR		X		[59]	
NOX-E36	CCL2		X		[60]	
Cyclophilin B	Secretome		X		[61]	
P12FR2	PAUF		X		[62]	
NOX-A12	CXCL12		X		[63]	
Non-specific	4-1BB	TNFSF9		X		[64]
	OX40	TNFSF4		X		[65]
	GL21.T	Axl domain		X		[66]
	Apt-siRNA	-		X		[67]
	CAR-like multivalent aptamer	-		X		[68]
	Bi-functional aptamers	Opsonin C3b/iC3b		X		[69]
	AS1411 and cyclic peptide	Alpha-v beta 3 (α v β 3)		X		[70]
	RGD	integrin α 5 β 1		X		[71]
	H02			X		[71]
	Dox-incorporated multivalent aptamer-siRNA conjugates	Multidrug resistance cancer		X		[72]
Ap52	MAGE-A3		X		[73,74]	

Abbreviations: HeA2-3: HER-positive Aptamer 2-3; PNDA-3: periostin Aptamer; apMNK2F/apMNK3R: aptamer against Mitogen-activated protein kinase-interacting kinases 2F and 3R; ex-50.T: aptamer targeting breast cancer exosomes; AS1411: ssDNA aptamer for nucleolin; YJ-1: alexa Fluor 488-labeled YJ-1 aptamer; apPDGF-BB: platelet-derived growth factor-BB aptamer; apPD-1: aptamer for PD1, protein of CD28 family; NOX-A12: L-stereoisomer RNA aptamer that binds and neutralizes CXCL12; aptPD-L1: aptamer for PD-L1, protein of CD28 family; AP-74 M-545: galectin-specific DNA aptamer; TBA353 and TBA535: aptamers that form G-quadruplex structures (no anticoagulant); RA16: aptamer that detects NCI-H460 cells; CL-4RNV616: aptamer that inhibit the proliferation of U87MG GBM cells by targeting EGFR; SW-4 and SW-4b: aptamer for RCC 786-O cells recognition; Apt63: aptamer that binds to the beta subunit of F1Fo ATP synthase; A9g and PSMA: aptamers for prostate specific membrane antigen; AGRO100: same as the AS1411 aptamer; CG3: aptamer that binds to PCA3 protein; 40L and A40s: 2'-fluoropyrimidine RNA aptamers; Anti-HPSE1: aptamer for HPSE-1; A2: antagonistic aptamer for β 2AR; alncRNA: aptamers that bind to β -catenin and NF- κ B; ap β -arrestin2: aptamer for β -arrestin2; ssRNA MLL-1: aptamer used for mixed-lineage leukemia 1; F3B: aptamer that recognizes MMP-9; 4-1BB: aptamer that stimulates CD8+ cells; OX40: aptamer that recognizes the tumor necrosis factor receptor superfamily; GL21.T: extracellular domain of Axl at high affinity binding aptamer; H02: aptamer that differentiate glioblastoma cell lines; HER2: Human Epidermal growth factor Receptor-type 2; MNK1: MAPK-interacting kinases 1; CEA: Carcinoembryonic antigen; PDGF-BB: platelet-derived growth factor-BB; PD-1: programmed cell death 1; CXCL12: chemokine C-X-C motif ligand 12; IFN- γ : Interferon-gamma; TBA: thrombin binding aptamer; NSCLC: non-small cell lung cancer;

EGFR: epidermal growth factor receptor; APT5B: beta subunit of F1Fo ATP synthase; PSMA: Prostate-specific membrane antigen; PCA3: Prostate cancer antigen 3; TFs: transcription factors; ErbB: epidermal growth factor related protein; MLL-1: Mixed lineage leukemia protein 1; MMP-9: Matrix metalloproteinase-9; C/EBP α : CCAAT/enhancer-binding protein α ; saRNA: small activating RNA; hTfR: human transferrin receptor; PDAC: pancreatic ductal adenocarcinoma; ALPP: alkaline phosphatase placental; EpCAM: epithelial cell adhesion molecule; CCL2: C-C Motif Chemokine Ligand 2; PAUF: Pancreatic adenocarcinoma upregulated factor; TNFSF: tumor necrosis factor superfamily; MAGE-A3: Melanoma antigen family A, 3.

For breast cancer, some aptamers have been studied. HeA2-3 is an aptamer used to target HER2, one of the most relevant receptors against this cancer, which inhibits the growth and survival of breast cancer cells [14]. PNDA-3 aptamer targets periostin and effectively inhibits breast cancer cell invasion and metastasis *in vivo*, despite limited *in vitro* growth effects [15]. Two aptamers target the MNK1, an essential component for cancer growth, apMNK2F, which has proven to be effective in decreasing both tumor size and the incidence of metastases in murine breast cancer models [16], and apMNK3R [17]. The aptamer ex-50.T is used to target the exosomes released by cancer tissue, reducing the molecular pathways that promote cancer proliferation such as AKT/Pi3K pathway [18]. In addition, 2'-Fluoropyrimidines-RNA aptamer is used conjugated with nanoparticles and allows treatment with photothermal therapy in triple-negative breast cancer cells [19]. The AS1411 aptamer targets nucleolin, which leads to the reduction in angiogenesis capacity, i.e., the capacity of producing new vessels to create a better microenvironment for tumoral development [20].

In colorectal cancer, four aptamers with the highest potential were identified. These were aptamer YJ-1, which binds to Carcinoembryonic antigen (CEA) and death receptor 5 and leads to the inhibition of tumor growth and migration potential [21]; apPDGF-BB, which is an aptamer for PDGF-BB and is important in reducing proliferation capacity [22]; another aptamer studied is apPD-1, which targets the PD-1 receptor, which leads to the activation of immune system [23]; and the last aptamer is NOX-A12, which inactivates CXCL12, showing promising results in the following studies [24].

Lung cancer is another cancer with high concern for new therapeutics due to its aggressiveness and lack of early detection strategies. However, several candidates have been identified as promising recognition elements. For example, aptPD-L1 targets the PD-L1 receptor and regulates the tumor microenvironment, stimulating the immune system cells [25] and AP-74 M-545 aptamer is used against galectin-1, also stimulating the immune system. In LL/2 tumors *in vivo*, it effectively inhibits tumor growth by reducing T cell apoptosis [26]. Two aptamers known as TBA353 and TBA535 target TBA, leading to reduced proliferation and invasive potential in lung cancer cell lines [27] and a PEGylated aptamer called RA16 is used specifically to bind to non-small-cell lung cancer cells, leading to tumor growth suppression [28].

Cancer of the liver also has some potential aptamers. For example, aptamer AS1411 [29] and AS1411-modified [30] target nucleolin and galectin-14, respectively, leading to a reduction in the tumoral features, in both *in vitro* and *in vivo* models, and the CL-4RNV616 aptamer targets EGFr, reduces proliferation, and promotes cell apoptosis [31].

Considering renal cancer, some aptamers are described. SW-4 and SW-4b are two aptamers used to modulate the endocytosis process of renal cancer cells, inducing their apoptosis and cell cycle [32]. The aptamer AS1411, currently in phase II clinical trials which have shown high potentiality in other cancers, can also induce a reduction in aggression [33].

Regarding prostate cancer, several studies have focused on the finding of new aptamers, since this cancer affects millions of men. Apt63 aptamer targets APT5B to reduce its metastatic potential and leads to cancer cell death, with no toxicity in non-tumoral cells, both in cell lines and in xenograft models [34]; two aptamer target PSMA, namely A9g [35] and other PSMA-specific aptamers [36], which is considered to have high potential against this cancer type, since PSMA is specific to prostate cancer tissue; combining A9g

with AGRO100, the inhibition of cancer features seems to be highly improved [37]; CG3 is an aptamer that inhibits the proliferation of blood cancer cells originated in prostate, showing potential both as a diagnostic tool for prostate cancer and as a drug delivery therapy system [38]; the AS1411 also expresses impact on prostate cancer [39]; finally, the shRNA/PEI-PEG-APT/DOX conjugates can detect and inactivate PSMA-positive cancer cells [40].

Regarding other types of cancer, there are aptamers that exhibit potential in treatment and/or diagnosis. For glioblastoma, 40L and A40s target CD133 and allow the reduction in metastasis process [41]; in oral cancer, the inhibition of Heparinase by the anti-HPSE1 seemed to be effective to reduce invasion capacity and lead to cytotoxicity of cancer cells [42]; regarding cervical cancer, A2 aptamer targets E6 and E7 oncogenes, which lead to tumor regression and growth inhibition [43]; concerning bladder cancer, alncRNA aptamer inhibits TF transcription and oncogene activity, leading to reduced cancer features [44]; and, in view of gastric cancer, the use of trimeric aptamer targets to ErbB-2/HER2, showing high efficiency when combined in the trimeric form, reducing endocytosis and growth rate [45]. Leukemia has some potential aptamers, such as AS1411 [46], $\alpha\beta$ -arrestin2 for the reduction in the progression of chronic myeloid leukemia [47], and ssRNA MLL-1 to target MLL-1, leading to cancer growth reduction [48]. For Hodgkin's lymphoma, an aptamer for CD30 is used to diagnose the disease, namely the CD-RNA aptamer with gold nanospheres called HAuNS [49]. In the myeloma disease, the use of NOX-A12, which targets CXCL12, leads to a reduction in cell adhesion and signaling processes, as well as cancer cell growth and proliferation [17], a phase IIa study in 28 relapsed/refractory multiple myeloma patients found NOX-A12, whether given alone or with bortezomib/dexamethasone, to be safe and well-tolerated [24]. Regarding skin cancer, F3B aptamers inhibit MMP-9, which reduces cell proliferation and extracellular matrix remodeling as well as allowing of the detection, being a theragnostic aptamer [50].

Pancreatic cancer is one of the leading causes of cancer death worldwide and is often diagnosed at an advanced stage with local invasion and distant metastases, which contribute to the high mortality rates associated with the disease [75,76]. The lack of effective treatments and diagnostic methods further compounds the problem, underscoring the need to develop targeted therapeutics and diagnostic approaches to improve patient outcomes [63]. Aptamers are, therefore, an attractive option for developing more accurate diagnostic tests and more effective treatments for pancreatic cancer.

The E07 aptamer, which targets the epidermal growth factor receptor (EGFR), can be used to improve the effectiveness of gemcitabine, having the potential to be a more effective treatment for pancreatic cancer than current therapies using gemcitabine alone [51]. Two RNA aptamers (P19 and P1) were selected to specifically recognize pancreatic cancer cells and deliver a duplex C/EBP α -saRNA molecule to target tumor growth suppression. In animal models, P19-C/EBP α -saRNA induced a 40% decrease in tumor growth with no toxicity [52]. A TfR aptamer-C/EBP α -saRNA conjugate used to treat advanced PDAC in a mouse model, also showed a significant reduction in tumor size [53]. Aptamer XQ-2d enables the conjugate to specifically recognize and enter PDAC cells, minimizing its side-effects on normal tissues. XQ-2d-His-SH2 CM-(Arg)9 conjugate impairs the ability of pancreatic cancer cells to undergo epithelial-mesenchymal transition (EMT), inhibiting the proliferation, invasion, and metastasis of PDAC cells [54].

SQ2, is an RNA aptamer with the capacity to be internalized by tumoral cells through ALPPL2-mediated clathrin-independent pathways [55]. This aptamer is capable of carrying a cytotoxic drug, demonstrating potential applications in imaging and therapeutics for all cancers that have aberrant expression of ALPPL2 [55,56]. The aptamers (1 and 146) colocalized with existing Cancer Stem Cell (CSC) markers, such as CD44, CD24, EpCAM, and CD133, which can recognize CSC marker-enriched Circulating Tumor Cells (CTCs) in pancreatic cancer, suggesting potential applications in pancreatic cancer diagnosis and treatment [57]. The X-aptamer targeting the Thy-1 membrane glycoprotein (THY1), overex-

pressed in pancreatic cancer cells, provides a non-immunogenic and specific option in the context of biomarker development and clinical application [58].

Additionally, some other aptamers are being tested. The aptamer aptacoy binds to the TfR, leading to an enhancement in the therapeutic response of Doxorubicin [59]; NOX-E36 aptamer connects to CCL2 and can be used not only in pancreatic tumors, but also in Diabetes mellitus type 2 (T2DM) [60]; cancer cell secretome can be detected and differentiated from healthy cells using the cyclophilin B aptamer [61]; the P12FR2 aptamer binds to PAUF and reduces the growth and metastatic capacity of cancer cells [62]; the use of NOX-A12, which targets CXCL12, leads to the reduction in cell adhesion and signaling processes, as well as cancer cell growth and proliferation [63].

Aside from the specificity for cancer sites, there are some aptamers that are not specific to target tissues, but cancer cells. The aptamers 4-1BB, which targets TNFSF9 [64], and OX40, which binds to TNFSF9 [65], promote immunotherapy treatment. GL21.T is another aptamer which allows the improvement of cancer cells to endocytose drugs, as well as to promote tumor selectivity [66]; Two different aptamers, Apt-siRNA [67] and CAR-like multivalent aptamer [68], do not have a specific target, although they have the capacity to lead to anticancer effects; bi-functional aptamers target opsonin C3b/iC3b, resulting in cancer cell destruction [69]; the AS1411 aptamer and cyclic peptide RGD bind to Alpha v beta 3 ($\alpha v \beta 3$), inhibiting cell growth and proliferation [70]; the H02 aptamer targets $\alpha 5 \beta 1$, reducing invasion capacity [71]; and dox-incorporated multivalent aptamer-siRNA conjugates produce powerful anticancer effects [72].

Conversely, tumor cells express shared tumor-specific antigens, which can induce immune responses when presented with MHC molecules on the cell surface. MAGE-A3 is a tumor-specific antigen that is highly expressed in several types of cancer, including melanoma, esophageal carcinoma, gastric carcinoma, multiple myeloma, breast cancer, and pancreatic cancer, often associated with malignancy and poor prognosis. Wang et al. (2016) described a DNA aptamer against the shared tumor-specific antigen MAGE-A3, which discriminates multiple types of cancer cells from normal cells (Ap52) [73]. In 2021, Wang and his team demonstrated that Ap52 can effectively penetrate cancer cells and selectively deliver the anticancer drug Doxorubicin (Dox), causing cytotoxicity to multiple types of cancer cell, becoming a promising therapeutic delivery system for various tumors [74]. In addition, aptamers may provide combinatorial manipulation of cell immunity and drug targeting for cancer therapy, and a combination of aptamers targeting various shared tumor-specific antigens may be used to combat tumor heterogeneity [74,77].

2.1. Applications in Immune Diseases

The versatility of aptamers created an important opportunity for diverse application in the field of immunology both in diagnosis and therapy. Considering diagnostic techniques aptamers might be used for two main purposes: detection [49,78,79] and separation [80–82]. In therapy, aptamers have two other principal functions that include being a therapeutic drug itself [83] or being responsible for taking fewer drugs to treat the affected cell or organ and, in this way, reducing the need for higher doses of drugs that have relevant secondary effects [84–86].

The gold standard techniques for immune diagnosis are flow cytometry and Enzyme-linked Immunosorbent Assay (ELISA) [87] and aptamers present features useful for both strategies, offering a broad range of solutions for the detection of biomolecules like proteins, including immunoglobulins or membrane receptors [49,83,85,88], cells [80,81,89], or even Extracellular Vesicles (EVs) that have gained popularity in fighting diseases like cancer. For EVs, CD63 is being consistently used as one of the most promising targets for aptamers on the surfaces of EVs [79,82]. Aptamers might also be used for cell separation using, as an example, sorting equipment accoupled to flow cytometry, which is useful both as a diagnosis technique [80,81] and also for therapy purposes in techniques like immunotherapy or HIV therapy [80,90].

Nozari et al. already reported a broad range of immune cell markers that include the most common markers, like CD4 or CD8, and also some unusual ones. This might be useful for diagnosis, cell sorting, and even therapy in a huge variety of diseases like cancer, HIV, or autoimmune conditions [49] (Table 2).

Considering therapeutical strategies, aptamers might be a drug by themselves and although there is potential for exclusive use of aptamers as a therapy [83], the most common approach is using aptamers together as co-adjuvant therapy. For example, aptamer- T cells together with anti-PD1 immune-checkpoint monoclonal antibodies have a synergetic effect in reducing cancer, in vitro and in rats, and aptamer-linked small-interfering RNA chimeras to selectively knock down genes in mouse breast cancers [91,92]. This approach allows a decrease in dose in immunotherapy applications and, in this way, reduces the secondary effects of therapies that might cause a lot of discomfort and distress in patients [83,93,94]. Aptamers are used not only in order to destroy the disease agent, like a cancer cell [89], but are often used as immune modulators, reducing immune activity [86], targeting or influencing immune checkpoint inhibitors [89,95,96], and/or promoting immune cell activity and infiltration [91,97].

Table 2. Main aptamers used in different immune diseases.

Disease	Aptamer	Target	Technique	Application			References
				Diagnostic	Therapy	Theranostic	
Auto-immune Diseases	NA	IgE	Electrochemical Sensor	X			[98–100]
	NA	IgE	Optical Biosensor	X			[101,102]
	NA	IL-2	-			X	[103]
Multiple Cancers	Ap52	MAGE-A3	Drug Delivery			X	[73]
	rvCD71apt	CD71	Cell Separation	X			[81]
	rvCD8apt	CD8	Exosome Separation	X			[82]
	NA	CD63 (Exosome)	Flow Cytometry	X			[104]
Acute Promyelocytic Leukemia	NA	NB4 Cell Line	Flow cytometry			X	[78]
Lung Cancer	NA	CD63 (Exosome)	Flow Cytometry	X			[79]
HIV/Liquid Tumors	CD4 Aptamer	CD4	Cell Separation	X			[80]
HIV	CCR5 Aptamer	CCR5	Drug		X		[83]
Melanoma	AS1411	Nucleoline	Drug Delivery			X	[84]
Graft versus Host Disease	CD8AP17s	CD8	Drug Delivery		X		[86]
Breast Cancer	PDGFR β	Lymphocytes	Drug		X		[89]
Glioblastoma	4-1BB-OPN	Osteopontin	Drug		X		[97]
Infection and Inflammation	NA	C-Reactive Protein	Optical Biosensor	X			[105]

Abbreviations: NA: not applicable; IgE: Immunoglobulin E; IL-2: Interleukin-2; MAGE-A3: Melanoma antigen family A, 3.

Aptamers are also showing a lot of potential for drug delivery therapies, not only in immune context, but in general. This happens because aptamers are very versatile as drug-targeting tools and can be used with at least three relevant functions. Aptamers might be carriers for other drugs, allowing the encapsulation of drugs [106], might be used for targeting, allowing the drug to reach in higher quantity the compromised cell/organ [84–86], and also might be used as a gating system that induces the release of the therapeutic drug when arriving at the target [106].

The scientific community has already gathered a few examples of how useful strategies using aptamers can be. Despite that, the scale of production for aptamers is far away from competing against the scale and optimization that big pharmaceutical companies have already developed for antibodies, making the use of aptamers more of an industrial problem than a scientific issue [90,95,107].

2.2. Microbiota and Infection

The human microbiome is a vast collection of microorganisms that live inside the human body, with bacteria, viruses, fungi, protozoa, and archaea all involved in this environment, playing a crucial role in human health and disease [108]. The microbiota is involved in a variety of physiological processes, including digestion, metabolism, immune system development, and protection against pathogens, and their composition is influenced by several factors such as diet, age, genetics, and environment [108,109]. However, disruption of the microbiota can lead to an increased risk of infection, which is a major cause of morbidity and mortality worldwide, and it has also been associated with several diseases like cardiovascular and gastrointestinal diseases, neurological disorders, cancer, among others [110]. Understanding the microbiota and its interactions with the host is becoming an active area of research, with potential applications in the diagnosis and treatment of diseases. Therefore, the development of new tools for the detection and treatment of infections is of utmost importance.

The microbiota plays a crucial role in protecting against pathogens and preventing infections, competing with pathogenic microorganisms for resources and space and preventing them from colonizing and infecting the host, producing antimicrobial peptides that can kill or inhibit the growth of pathogenic microorganisms and modulate the immune system's response to pathogens [111,112]. However, when a disruption of this microbiota occurs, it can lead to harmful situations, particularly respiratory, gastrointestinal, and skin infections [111]. One example is antibiotics that can disrupt this balance, promoting pathogenic bacteria overgrowth and increased risk of infection, with *Streptococcus* and *Staphylococcus* being among the most common [113]. Also, the overgrowth of *Clostridium difficile* can lead to a severe infection, which can cause symptoms ranging from diarrhea to life-threatening complications [114].

Aptamers have been increasingly used in microbiome diagnostics, where they can identify and characterize the microorganisms present in a specific environment, such as the human gut, skin, or oral cavity, because of their unique binding properties and their ability to detect specific microbial biomarkers in complex biological samples [1]. Their use in the gut microbiota field has several advantages, including high sensitivity and specificity, easy modulation and synthesis, low cost, and high stability, making them valuable tools for studying the complex interactions between the microbiota and the host and help to develop personalized microbiota-based therapies [1,2].

One application of aptamers in microbiota research is the identification and quantification of specific microbial species or strains [115]. Aptamers can be designed to specifically bind to the surface molecules or antigens of certain bacteria or other microorganisms, facilitating the identification and quantification of those organisms [115]. This method can be particularly useful in identifying and monitoring specific pathogenic or beneficial microorganisms in complex microbial communities, with studies by Hu et al. and Song et al. describing this novel approach in strains like *Bifidobacterium bifidum* (CCFM641-5) and *Lactobacillus casei*, at the same time, demonstrating the potential of aptamer-based strategies for the rapid and accurate detection and quantification of bacteria in food products [116,117].

Another application of aptamers in microbiome research is the study of microbial metabolites and signaling molecules, where aptamers can be designed to specifically recognize and bind to small molecules, such as short-chain fatty acids, neurotransmitters, and other signaling molecules produced by the microbiota, where aptamers can profile and characterize at the species, strain, or function level. They can be used in combination with high-throughput sequencing technologies, such as 16S rRNA sequencing to identify and quantify specific microbial populations in the gut microbiota and to identify and quantify specific microbial metabolites, which are important for gut health [118]. This approach allows researchers to better understand the interactions between the microbiome and the host and how they influence overall health and disease, providing a more accurate diagnosis and better understanding of the disease [119–123].

Aptamers can also be used in therapy to target and modulate specific microorganisms, or to target drug delivery in the gut microbiota. For example, Wandtke et al. (2015) designed aptamers to selectively bind to viral proteins or other molecules involved in viral replication and infection with high specificity and sensitivity, preventing their replication or disrupting their functions [124]. Here, the authors discuss several examples of aptamer-based assays developed for the detection of hepatitis C and Human Immunodeficiency Virus (HIV) and also how this novel method could be used as a therapeutic agent for viral infections, such as influenza, with A-20 and V46 aptamers [119,120], dengue fever, with S15G3 aptamer [121], and Zika virus [122]. Additionally, aptamers can be used to deliver therapeutic molecules, such as antibiotics, antivirals, antifungals, or probiotics, specifically to the site of infection or dysbiosis in the human microbiota, reducing side effects and increasing efficacy [123]. They can also be used to deliver therapeutic nucleic acids, such as small interfering RNA (siRNA) or microRNA (miRNA), to downregulate the expression of viral genes or host cell genes that are essential for infection [124]. Several studies have also demonstrated the use of aptamers in detecting specific microbial targets in gastrointestinal dysbiosis, such as detecting *Clostridium difficile* with the ARH1t6 aptamer [125] in addition to using others to detect gut pathogens such as *Salmonella* [126] and *Escherichia coli* [127]. Aptamers have also shown potential in the treatment of gastrointestinal diseases, specifically targeting and inhibiting the growth or virulence of pathogens such as *Helicobacter pylori*, a bacterium known to cause peptic ulcer and gastric cancer. The aptamer HPA-2 has shown potential for the detection of *H. pylori*, demonstrating high specificity within a limit of detection of 88 cfu/mL [128]. In addition to the mentioned applications, aptamers can also be used to monitor changes in microbiota and detecting shifts in the microbial community, allowing for the identification of potential health risks or the monitoring of the effectiveness of treatments [129].

The use of aptamers in gut microbiota research is still in its early stages and there is significant potential for future applications. Aptamers have the potential to be used as a diagnostic tool for gut microbiota-related disease, such as inflammatory bowel disease and colorectal cancer, but also for gut microbiota-related diseases, such as antibiotic-resistant infections [123]. Moreover, aptamers can be integrated with other technologies, such as high-throughput sequencing and mass spectrometry, to provide a more comprehensive analysis of the gut microbiota [130]. This approach has the potential to provide a more detailed understanding of the gut microbiota and its role in human health and disease.

2.3. Final Remarks

The high affinity displayed by aptamer over their targets, and its facility in conjugating with labelling molecules makes them a suitable tool, acting as recognition elements, for biomarker discovery and disease diagnosis, especially in imaging and biosensor devices [8,9,11].

In the field of both in vivo and in vitro bioimaging, aptamers have advantages over antibodies, owing to their good solubility and low molecular weight when compared with antibodies, which allows its blood clearance and easy tissue penetration abilities [11,12].

Biosensors that use aptamers as recognition elements are called aptasensors and generally rely on the conformational changes in the aptamers after binding to its target. They have been applied in point-of-care miniaturized devices to detect environmental contaminants, cancer biomarkers or drugs, as example [85,131,132]. Additionally, they can also be used as a theragnostic tool, allowing to detect and treat cancer [133]. In terms of diagnosis, regardless the field of pathology, the main advantage in the application of the sensing strategy relies on early detection. Early detection allows, by itself a higher rate of success in overall survival. Moreover, since most diseases lack proper early diagnosis due to a lack of specific biomarkers, biosensors also allow the possibility of multiplexing analysis, helping eliminate inaccurate diagnoses [134], or even diagnosing diseases with higher feasibility [135]. Ultimately, this translates to proper and personalized therapy with fewer side effects and lower overall costs.

3. Conclusions

Aptamers, short synthetic single-stranded RNA or DNA molecules, have emerged as powerful tools with a wide range of applications in various fields, including cancer therapeutics, immune diseases, microbiota research, and diagnosis.

Within cancer therapeutics, aptamers have shown tremendous promise. They can act as antagonists or agonists, blocking or stimulating specific targets, making them valuable for drug delivery systems. Aptamers offer a more targeted and potentially less toxic alternative to traditional cancer treatments like chemotherapy. Their application spans various cancer types, with numerous aptamers having been identified to target specific markers associated with breast, colorectal, lung, liver, renal, prostate, and other cancers. The versatility of aptamers allows for their combination with other therapeutic agents, potentially enhancing treatment responses and reducing the likelihood of resistance.

Aptamers have also been found to have applications in the treatment of immune diseases, where they can be employed for diagnosis and therapy. They can detect immune markers, facilitating the diagnosis of conditions such as HIV or autoimmune diseases. Aptamers can also modulate immune responses, influence immune checkpoint inhibitors, or stimulate immune cells, contributing to more effective immunotherapies. Furthermore, aptamers have potential in drug delivery strategies, optimizing drug targeting, and minimizing side effects.

In microbiota research and infection control, aptamers play a pivotal role in identifying and quantifying specific microbial species or strains. Their high specificity and sensitivity allow for the rapid detection of pathogens or beneficial microorganisms in complex microbial communities. Aptamers can also target microbial metabolites and signal molecules, aiding in understanding the intricate interactions between the microbiome and host health. Additionally, they have applications in therapy, where they can target and modulate specific microorganisms or deliver therapeutic molecules precisely to infection sites, reducing side effects and improving treatment efficacy. Aptamers have the potential to revolutionize the study and management of microbiota-related diseases and infections.

Finally, aptamers are valuable tools for disease diagnosis, offering high affinity, ease of conjugation with labeling molecules, and versatility in biosensors and bioimaging. They outperform antibodies in various diagnostic applications, such as biosensors for detecting environmental contaminants, cancer biomarkers, or drugs. Aptasensors based on aptamer-conformational changes have been deployed in point-of-care devices, providing rapid and accurate detection, even in resource-limited settings. These aptamer-based diagnostic tools hold great promise for improving early disease detection and personalized medicine.

Overall, aptamers have transcended the confines of the laboratory and have emerged as indispensable components in various scientific disciplines. Their versatility, specificity, and applicability continue to expand, offering innovative solutions for tackling complex challenges in cancer research, immunology, microbiota analysis, and disease diagnosis. As research in aptamers continues to evolve, we can anticipate even more breakthroughs and advancements with profound implications for healthcare, diagnostics, and therapeutic interventions.

Author Contributions: A.P.S.: Data research, original draft preparation; A.C.R.: Data research, original draft preparation; C.A.: Data research, original draft preparation; M.C.C.G.C.: Data research, original draft preparation; P.P.P.: Data research, original draft preparation; R.V.: Data research, original draft preparation; R.F.: Reviewing and editing; P.B. (Pedro Barata): Reviewing; Á.G.: Editing; S.R.: Research; D.M.-M.: Research; P.B. (Pilar Baylina): Conceptualization, research, reviewing, and editing. A.C.P.: Conceptualization, reviewing, and editing. All authors have read and agreed to the published version of the manuscript.

Funding: Pilar Baylina (P.B.) acknowledges on the behalf of the authors the support of Fundação para a Ciência e Tecnologia (FCT), Portuguese Government, under the Strategic Project Reference: UID/BIM/04293/2013. Pilar Baylina (P.B.) and R.F. was also supported by FEDER/02/SAICT/2020/072560. Ana Cláudia Pereira (A.C.P.) acknowledges the support of Fundação para a Ciência e

Tecnologia (FCT), Portuguese Government, under the Strategic Project Reference: 2022.09032.PTDC. André P. Sousa acknowledges FCT for the PhD grant 2022.12441.BD. Ana C. Rocha acknowledges FCT for the PhD grant 2021.06521.BD. Patrick P. Pais acknowledges FCT for the PhD grant 2021.09498.BD. Susana Ramalho acknowledges LaBMI for the PhD grant LABMI/BI/2021/01 (NEURO4COVID).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All the data presented in this study are openly available in PubMed, NCBI. The DOI for each study is presented on the references.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Kumar Kulabhusan, P.A.-O.; Hussain, B.; Yuce, M. Current Perspectives on Aptamers as Diagnostic Tools and Therapeutic Agents. *Pharmaceutics* **2020**, *12*, 646. [[CrossRef](#)] [[PubMed](#)]
2. Byun, J. Recent Progress and Opportunities for Nucleic Acid Aptamers. *Life* **2021**, *11*, 193. [[CrossRef](#)] [[PubMed](#)]
3. Tuerk, C.; Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. *Science* **1990**, *249*, 505–510. [[CrossRef](#)] [[PubMed](#)]
4. Ellington, A.D.; Szostak, J.W. In vitro selection of RNA molecules that bind specific ligands. *Nature* **1990**, *346*, 818–822. [[CrossRef](#)]
5. Sousa, D.A.; Carneiro, M.; Ferreira, D.; Moreira, F.T.C.; Sales, M.G.F.; Rodrigues, L.R. Recent Advances in the Selection of Cancer-Specific Aptamers for the Development of Biosensors. *Curr. Med. Chem.* **2022**, *29*, 5850–5880. [[CrossRef](#)]
6. Agnello, L.; Camorani, S.; Fedele, M.; Cerchia, L. Aptamers and antibodies: Rivals or allies in cancer targeted therapy? *Explor. Target. Antitumor Ther.* **2021**, *2*, 107–121. [[CrossRef](#)]
7. Thevendran, R.; Citartan, M. Assays to Estimate the Binding Affinity of Aptamers. *Talanta* **2022**, *238*, 122971. [[CrossRef](#)]
8. Ozer, A.; Pagano, J.M.; Lis, J.T. New Technologies Provide Quantum Changes in the Scale, Speed, and Success of SELEX Methods and Aptamer Characterization. *Mol. Ther. Nucleic Acids* **2014**, *3*, e183. [[CrossRef](#)] [[PubMed](#)]
9. Zhuo, Z.; Yu, Y.; Wang, M.; Li, J.; Zhang, Z.; Liu, J.; Wu, X.; Lu, A.; Zhang, G.; Zhang, B. Recent Advances in SELEX Technology and Aptamer Applications in Biomedicine. *Int. J. Mol. Sci.* **2017**, *18*, 2142. [[CrossRef](#)]
10. Radom, F.; Jurek, P.M.; Mazurek, M.P.; Otlewski, J.; Jelen, F. Aptamers: Molecules of great potential. *Biotechnol. Adv.* **2013**, *31*, 1260–1274. [[CrossRef](#)]
11. Santosh, B.; Yadava, P.K. Nucleic acid aptamers: Research tools in disease diagnostics and therapeutics. *Biomed. Res. Int.* **2014**, *2014*, 540451. [[CrossRef](#)]
12. Sun, H.; Zu, Y. A Highlight of Recent Advances in Aptamer Technology and Its Application. *Molecules* **2015**, *20*, 11959–11980. [[CrossRef](#)] [[PubMed](#)]
13. Wu, Y.X.; Kwon, Y.J. Aptamers: The “evolution” of SELEX. *Methods* **2016**, *106*, 21–28. [[CrossRef](#)]
14. Gijs, M.; Penner, G.; Blackler, G.B.; Impens, N.R.; Baatout, S.; Luxen, A.; Aerts, A.M. Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer. *Pharmaceutics* **2016**, *9*, 29. [[CrossRef](#)]
15. Lee, Y.J.; Kim, I.S.; Park, S.A.; Kim, Y.; Lee, J.E.; Noh, D.Y.; Kim, K.T.; Ryu, S.H.; Suh, P.G. Periostin-binding DNA aptamer inhibits breast cancer growth and metastasis. *Mol. Ther.* **2013**, *21*, 1004–1013. [[CrossRef](#)]
16. Pinto-Diez, C.; Ferreras-Martin, R.; Carrion-Marchante, R.; Klett-Mingo, J.I.; Garcia-Hernandez, M.; Perez-Morgado, M.I.; Sacristan, S.; Barragan, M.; Seijo-Vila, M.; Tundidor, I.; et al. An optimized MNK1b aptamer, apMNKQ2, and its potential use as a therapeutic agent in breast cancer. *Mol. Ther. Nucleic Acids* **2022**, *30*, 553–568. [[CrossRef](#)] [[PubMed](#)]
17. Li, Z.; Fu, X.; Huang, J.; Zeng, P.; Huang, Y.; Chen, X.; Liang, C. Advances in Screening and Development of Therapeutic Aptamers Against Cancer Cells. *Front. Cell Dev. Biol.* **2021**, *9*, 662791. [[CrossRef](#)]
18. Esposito, C.L.; Quintavalle, C.; Ingenito, F.; Rotoli, D.; Roscigno, G.; Nuzzo, S.; Thomas, R.; Catuogno, S.; de Franciscis, V.; Condorelli, G. Identification of a novel RNA aptamer that selectively targets breast cancer exosomes. *Mol. Ther. Nucleic Acids* **2021**, *23*, 982–994. [[CrossRef](#)]
19. Aldag, J.; Persson, T.; Hartmann, R.K. 2'-Fluoro-Pyrimidine-Modified RNA Aptamers Specific for Lipopolysaccharide Binding Protein (LBP). *Int. J. Mol. Sci.* **2018**, *19*, 3883. [[CrossRef](#)] [[PubMed](#)]
20. Soundararajan, S.; Chen, W.; Spicer, E.K.; Courtenay-Luck, N.; Fernandes, D.J. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. *Cancer Res.* **2008**, *68*, 2358–2365. [[CrossRef](#)]
21. Viraka Nellore, B.P.; Kanchanapally, R.; Pramanik, A.; Sinha, S.S.; Chavva, S.R.; Hamme, A., 2nd; Ray, P.C. Aptamer-conjugated graphene oxide membranes for highly efficient capture and accurate identification of multiple types of circulating tumor cells. *Bioconjug Chem.* **2015**, *26*, 235–242. [[CrossRef](#)]
22. Sae-Lim, S.; Soontornworajit, B.; Rotkrua, P. Inhibition of Colorectal Cancer Cell Proliferation by Regulating Platelet-Derived Growth Factor B Signaling with a DNA Aptamer. *Asian Pac. J. Cancer Prev.* **2019**, *20*, 487–494. [[CrossRef](#)] [[PubMed](#)]
23. Ahmadyousefi, Y.; Malih, S.; Mirzaee, Y.; Saidijam, M. Nucleic acid aptamers in diagnosis of colorectal cancer. *Biochimie* **2019**, *156*, 1–11. [[CrossRef](#)]

24. Kaur, H.; Bruno, J.G.; Kumar, A.; Sharma, T.K. Aptamers in the Therapeutics and Diagnostics Pipelines. *Theranostics* **2018**, *8*, 4016–4032. [[CrossRef](#)]
25. Lai, W.Y.; Huang, B.T.; Wang, J.W.; Lin, P.Y.; Yang, P.C. A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects. *Mol. Ther. Nucleic Acids* **2016**, *5*, e397. [[CrossRef](#)] [[PubMed](#)]
26. Tsai, Y.T.; Liang, C.H.; Yu, J.H.; Huang, K.C.; Tung, C.H.; Wu, J.E.; Wu, Y.Y.; Chang, C.H.; Hong, T.M.; Chen, Y.L. A DNA Aptamer Targeting Galectin-1 as a Novel Immunotherapeutic Strategy for Lung Cancer. *Mol. Ther. Nucleic Acids* **2019**, *18*, 991–998. [[CrossRef](#)] [[PubMed](#)]
27. Esposito, V.; Russo, A.; Vellecco, V.; Bucci, M.; Russo, G.; Mayol, L.; Virgilio, A.; Galeone, A. Thrombin binding aptamer analogues containing inversion of polarity sites endowed with antiproliferative and anti-motility properties against Calu-6 cells. *Biochim. Biophys. Acta Gen. Subj.* **2018**, *1862*, 2645–2650. [[CrossRef](#)]
28. Wang, H.; Qin, M.; Liu, R.; Ding, X.; Chen, I.S.Y.; Jiang, Y. Characterization of A Bifunctional Synthetic RNA Aptamer and A Truncated Form for Ability to Inhibit Growth of Non-Small Cell Lung Cancer. *Sci. Rep.* **2019**, *9*, 18836. [[CrossRef](#)]
29. Trinh, T.L.; Zhu, G.; Xiao, X.; Puszyk, W.; Sefah, K.; Wu, Q.; Tan, W.; Liu, C. A Synthetic Aptamer-Drug Adduct for Targeted Liver Cancer Therapy. *PLoS ONE* **2015**, *10*, e0136673. [[CrossRef](#)]
30. Yazdian-Robati, R.; Bayat, P.; Oroojalian, F.; Zargari, M.; Ramezani, M.; Taghdisi, S.M.; Abnous, K. Therapeutic applications of AS1411 aptamer, an update review. *Int. J. Biol. Macromol.* **2020**, *155*, 1420–1431. [[CrossRef](#)]
31. Wang, T.; Philippovich, S.; Mao, J.; Veedu, R.N. Efficient Epidermal Growth Factor Receptor Targeting Oligonucleotide as a Potential Molecule for Targeted Cancer Therapy. *Int. J. Mol. Sci.* **2019**, *20*, 4700. [[CrossRef](#)] [[PubMed](#)]
32. Zhang, H.; Wang, Z.; Xie, L.; Zhang, Y.; Deng, T.; Li, J.; Liu, J.; Xiong, W.; Zhang, L.; Zhang, L.; et al. Molecular Recognition and In-Vitro-Targeted Inhibition of Renal Cell Carcinoma Using a DNA Aptamer. *Mol. Ther. Nucleic Acids* **2018**, *12*, 758–768. [[CrossRef](#)] [[PubMed](#)]
33. Rosenberg, J.E.; Bambury, R.M.; Van Allen, E.M.; Drabkin, H.A.; Lara, P.N., Jr.; Harzstark, A.L.; Wagle, N.; Figlin, R.A.; Smith, G.W.; Garraway, L.A.; et al. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. *Investig. New Drugs* **2014**, *32*, 178–187. [[CrossRef](#)] [[PubMed](#)]
34. Speransky, S.; Serafini, P.; Caroli, J.; Biciato, S.; Lippman, M.E.; Bishopric, N.H. A novel RNA aptamer identifies plasma membrane ATP synthase beta subunit as an early marker and therapeutic target in aggressive cancer. *Breast Cancer Res. Treat.* **2019**, *176*, 271–289. [[CrossRef](#)] [[PubMed](#)]
35. Dassie, J.P.; Hernandez, L.I.; Thomas, G.S.; Long, M.E.; Rockey, W.M.; Howell, C.A.; Chen, Y.; Hernandez, F.J.; Liu, X.Y.; Wilson, M.E.; et al. Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen. *Mol. Ther.* **2014**, *22*, 1910–1922. [[CrossRef](#)]
36. Jiao, Y.; Xu, P.; Luan, S.; Wang, X.; Gao, Y.; Zhao, C.; Fu, P. Molecular imaging and treatment of PSMA-positive prostate cancer with (99m)Tc radiolabeled aptamer-siRNA chimeras. *Nucl. Med. Biol.* **2022**, *104–105*, 28–37. [[CrossRef](#)]
37. Singh, S.S. Preclinical pharmacokinetics: An approach towards safer and efficacious drugs. *Curr. Drug Metab.* **2006**, *7*, 165–182. [[CrossRef](#)]
38. Marangoni, K.; Neves, A.F.; Rocha, R.M.; Faria, P.R.; Alves, P.T.; Souza, A.G.; Fujimura, P.T.; Santos, F.A.; Araujo, T.G.; Ward, L.S.; et al. Prostate-specific RNA aptamer: Promising nucleic acid antibody-like cancer detection. *Sci. Rep.* **2015**, *5*, 12090. [[CrossRef](#)]
39. Reyes-Reyes, E.M.; Salipur, F.R.; Shams, M.; Forsthoefel, M.K.; Bates, P.J. Mechanistic studies of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation. *Mol. Oncol.* **2015**, *9*, 1392–1405. [[CrossRef](#)]
40. Kim, E.; Jung, Y.; Choi, H.; Yang, J.; Suh, J.S.; Huh, Y.M.; Kim, K.; Haam, S. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. *Biomaterials* **2010**, *31*, 4592–4599. [[CrossRef](#)]
41. Affinito, A.; Quintavalle, C.; Esposito, C.L.; Roscigno, G.; Vilaro, C.; Nuzzo, S.; Ricci-Vitiani, L.; De Luca, G.; Pallini, R.; Kichkailo, A.S.; et al. The Discovery of RNA Aptamers that Selectively Bind Glioblastoma Stem Cells. *Mol. Ther. Nucleic Acids* **2019**, *18*, 99–109. [[CrossRef](#)]
42. Vayrynen, O.; Piippo, M.; Jamsa, H.; Vaisanen, T.; de Almeida, C.E.B.; Salo, T.; Missailidis, S.; Risteli, M. Effects of ionizing radiation and HPSE1 inhibition on the invasion of oral tongue carcinoma cells on human extracellular matrices in vitro. *Exp. Cell Res.* **2018**, *371*, 151–161. [[CrossRef](#)]
43. Cesur, O.; Nicol, C.; Groves, H.; Mankouri, J.; Blair, G.E.; Stonehouse, N.J. The Subcellular Localisation of the Human Papillomavirus (HPV) 16 E7 Protein in Cervical Cancer Cells and Its Perturbation by RNA Aptamers. *Viruses* **2015**, *7*, 3443–3461. [[CrossRef](#)] [[PubMed](#)]
44. Wang, Y.; Zhang, Y.; Li, P.C.; Guo, J.; Huo, F.; Yang, J.; Jia, R.; Wang, J.; Huang, Q.; Theodorescu, D.; et al. Development of Novel Aptamer-Based Targeted Chemotherapy for Bladder Cancer. *Cancer Res.* **2022**, *82*, 1128–1139. [[CrossRef](#)] [[PubMed](#)]
45. Mahlknecht, G.; Maron, R.; Mancini, M.; Schechter, B.; Sela, M.; Yarden, Y. Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 8170–8175. [[CrossRef](#)]
46. Soundararajan, S.; Wang, L.; Sridharan, V.; Chen, W.; Courtenay-Luck, N.; Jones, D.; Spicer, E.K.; Fernandes, D.J. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells. *Mol. Pharmacol.* **2009**, *76*, 984–991. [[CrossRef](#)]
47. Kotula, J.W.; Sun, J.; Li, M.; Pratico, E.D.; Fereshteh, M.P.; Ahrens, D.P.; Sullenger, B.A.; Kovacs, J.J. Targeted disruption of beta-arrestin 2-mediated signaling pathways by aptamer chimeras leads to inhibition of leukemic cell growth. *PLoS ONE* **2014**, *9*, e93441. [[CrossRef](#)]

48. Ul-Haq, A.; Jin, M.L.; Jeong, K.W.; Kim, H.M.; Chun, K.H. Isolation of MLL1 Inhibitory RNA Aptamers. *Biomol. Ther.* **2019**, *27*, 201–209. [[CrossRef](#)] [[PubMed](#)]
49. Nozari, A.; Berezovski, M.V. Aptamers for CD Antigens: From Cell Profiling to Activity Modulation. *Mol. Ther. Nucleic Acids* **2017**, *6*, 29–44. [[CrossRef](#)]
50. Kryza, D.; Debordeaux, F.; Azema, L.; Hassan, A.; Paurelle, O.; Schulz, J.; Savona-Baron, C.; Charignon, E.; Bonazza, P.; Taleb, J.; et al. Ex Vivo and In Vivo Imaging and Biodistribution of Aptamers Targeting the Human Matrix MetalloProtease-9 in Melanomas. *PLoS ONE* **2016**, *11*, e0149387. [[CrossRef](#)]
51. Ray, P.; Cheek, M.A.; Sharaf, M.L.; Li, N.; Ellington, A.D.; Sullenger, B.A.; Shaw, B.R.; White, R.R. Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells. *Nucleic Acid. Ther.* **2012**, *22*, 295–305. [[CrossRef](#)] [[PubMed](#)]
52. Yoon, S.; Huang, K.W.; Reebye, V.; Mintz, P.; Tien, Y.W.; Lai, H.S.; Saetrom, P.; Reccia, I.; Swiderski, P.; Armstrong, B.; et al. Targeted Delivery of C/EBPalpha -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo. *Mol. Ther.* **2016**, *24*, 1106–1116. [[CrossRef](#)] [[PubMed](#)]
53. Yoon, S.; Huang, K.W.; Andrikakou, P.; Vasconcelos, D.; Swiderski, P.; Reebye, V.; Sodergren, M.; Habib, N.; Rossi, J.J. Targeted Delivery of C/EBPalpha-saRNA by RNA Aptamers Shows Anti-tumor Effects in a Mouse Model of Advanced PDAC. *Mol. Ther. Nucleic Acids* **2019**, *18*, 142–154. [[CrossRef](#)]
54. Liu, A.D.; Zhou, J.; Bi, X.Y.; Hou, G.Q.; Li, S.S.; Chen, Q.; Xu, H.; Cao, X. Aptamer-SH2 superbinder-based targeted therapy for pancreatic ductal adenocarcinoma. *Clin. Transl. Med.* **2021**, *11*, e337. [[CrossRef](#)]
55. Dua, P.; Kang, H.S.; Hong, S.M.; Tsao, M.S.; Kim, S.; Lee, D.K. Alkaline phosphatase ALPPL-2 is a novel pancreatic carcinoma-associated protein. *Cancer Res.* **2013**, *73*, 1934–1945. [[CrossRef](#)] [[PubMed](#)]
56. Dua, P.; Sajeesh, S.; Kim, S.; Lee, D.K. ALPPL2 Aptamer-Mediated Targeted Delivery of 5-Fluoro-2'-Deoxyuridine to Pancreatic Cancer. *Nucleic Acid. Ther.* **2015**, *25*, 180–187. [[CrossRef](#)]
57. Kim, Y.J.; Lee, H.S.; Jung, D.E.; Kim, J.M.; Song, S.Y. The DNA aptamer binds stemness-enriched cancer cells in pancreatic cancer. *J. Mol. Recognit.* **2017**, *30*, e2591. [[CrossRef](#)]
58. Wang, H.; Li, X.; Lai, L.A.; Brentnall, T.A.; Dawson, D.W.; Kelly, K.A.; Chen, R.; Pan, S. X-aptamers targeting Thy-1 membrane glycoprotein in pancreatic ductal adenocarcinoma. *Biochimie* **2021**, *181*, 25–33. [[CrossRef](#)]
59. Porciani, D.; Tedeschi, L.; Marchetti, L.; Citti, L.; Piazza, V.; Beltram, F.; Signore, G. Aptamer-Mediated Codelivery of Doxorubicin and NF-kappaB Decoy Enhances Chemosensitivity of Pancreatic Tumor Cells. *Mol. Ther. Nucleic Acids* **2015**, *4*, e235. [[CrossRef](#)]
60. Citro, A.; Pellegrini, S.; Dugnani, E.; Eulberg, D.; Klusmann, S.; Piemonti, L. CCL2/MCP-1 and CXCL12/SDF-1 blockade by L-aptamers improve pancreatic islet engraftment and survival in mouse. *Am. J. Transpl.* **2019**, *19*, 3131–3138. [[CrossRef](#)]
61. Ray, P.; Sullenger, B.A.; White, R.R. Further characterization of the target of a potential aptamer biomarker for pancreatic cancer: Cyclophilin B and its posttranslational modifications. *Nucleic Acid. Ther.* **2013**, *23*, 435–442. [[CrossRef](#)] [[PubMed](#)]
62. Kim, Y.H.; Sung, H.J.; Kim, S.; Kim, E.O.; Lee, J.W.; Moon, J.Y.; Choi, K.; Jung, J.E.; Lee, Y.; Koh, S.S.; et al. An RNA aptamer that specifically binds pancreatic adenocarcinoma up-regulated factor inhibits migration and growth of pancreatic cancer cells. *Cancer Lett.* **2011**, *313*, 76–83. [[CrossRef](#)] [[PubMed](#)]
63. Morita, Y.; Leslie, M.; Kameyama, H.; Volk, D.E.; Tanaka, T. Aptamer Therapeutics in Cancer: Current and Future. *Cancers* **2018**, *10*, 80. [[CrossRef](#)] [[PubMed](#)]
64. Compte, M.; Harwood, S.L.; Munoz, I.G.; Navarro, R.; Zonca, M.; Perez-Chacon, G.; Erce-Llamazares, A.; Merino, N.; Tapiá-Galisteo, A.; Cuesta, A.M.; et al. A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity. *Nat. Commun.* **2018**, *9*, 4809. [[CrossRef](#)] [[PubMed](#)]
65. Dollins, C.M.; Nair, S.; Boczkowski, D.; Lee, J.; Layzer, J.M.; Gilboa, E.; Sullenger, B.A. Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. *Chem. Biol.* **2008**, *15*, 675–682. [[CrossRef](#)]
66. Cerchia, L.; Esposito, C.L.; Camorani, S.; Rienzo, A.; Stasio, L.; Insabato, L.; Affuso, A.; de Franciscis, V. Targeting Axl with an high-affinity inhibitory aptamer. *Mol. Ther.* **2012**, *20*, 2291–2303. [[CrossRef](#)]
67. Dinis Ano Bom, A.P.; da Costa Neves, P.C.; Bonacossa de Almeida, C.E.; Silva, D.; Missailidis, S. Aptamers as Delivery Agents of siRNA and Chimeric Formulations for the Treatment of Cancer. *Pharmaceutics* **2019**, *11*, 684. [[CrossRef](#)]
68. Bai, C.; Gao, S.; Hu, S.; Liu, X.; Li, H.; Dong, J.; Huang, A.; Zhu, L.; Zhou, P.; Li, S.; et al. Self-Assembled Multivalent Aptamer Nanoparticles with Potential CAR-like Characteristics Could Activate T Cells and Inhibit Melanoma Growth. *Mol. Ther. Oncolytics* **2020**, *17*, 9–20. [[CrossRef](#)]
69. Macdonald, J.; Henri, J.; Goodman, L.; Xiang, D.; Duan, W.; Shigdar, S. Development of a Bifunctional Aptamer Targeting the Transferrin Receptor and Epithelial Cell Adhesion Molecule (EpCAM) for the Treatment of Brain Cancer Metastases. *ACS Chem. Neurosci.* **2017**, *8*, 777–784. [[CrossRef](#)]
70. Ma, Y.; Ai, G.; Zhang, C.; Zhao, M.; Dong, X.; Han, Z.; Wang, Z.; Zhang, M.; Liu, Y.; Gao, W.; et al. Novel Linear Peptides with High Affinity to alphavbeta3 Integrin for Precise Tumor Identification. *Theranostics* **2017**, *7*, 1511–1523. [[CrossRef](#)]
71. Fechter, P.; Cruz Da Silva, E.; Mercier, M.C.; Noulet, F.; Etienne-Seloum, N.; Guenot, D.; Lehmann, M.; Vauchelles, R.; Martin, S.; Lelong-Rebel, I.; et al. RNA Aptamers Targeting Integrin alpha5beta1 as Probes for Cyto- and Histofluorescence in Glioblastoma. *Mol. Ther. Nucleic Acids* **2019**, *17*, 63–77. [[CrossRef](#)] [[PubMed](#)]
72. Jeong, H.; Lee, S.H.; Hwang, Y.; Yoo, H.; Jung, H.; Kim, S.H.; Mok, H. Multivalent Aptamer-RNA Conjugates for Simple and Efficient Delivery of Doxorubicin/siRNA into Multidrug-Resistant Cells. *Macromol. Biosci.* **2017**, *17*, 1600343. [[CrossRef](#)]

73. Wang, C.Y.; Lin, B.L.; Chen, C.H. An aptamer targeting shared tumor-specific peptide antigen of MAGE-A3 in multiple cancers. *Int. J. Cancer* **2016**, *138*, 918–926. [[CrossRef](#)] [[PubMed](#)]
74. Wang, C.Y.; Lin, B.L.; Chen, C.H. Targeted drug delivery using an aptamer against shared tumor-specific peptide antigen of MAGE-A3. *Cancer Biol. Ther.* **2021**, *22*, 12–18. [[CrossRef](#)] [[PubMed](#)]
75. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J. Clin.* **2021**, *71*, 209–249. [[CrossRef](#)]
76. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. *CA Cancer J. Clin.* **2020**, *70*, 7–30. [[CrossRef](#)]
77. Liu, Z.; Parveen, N.; Rehman, U.; Aziz, A.; Sheikh, A.; Abourehab, M.A.S.; Guo, W.; Huang, J.; Wang, Z.; Kesharwani, P. Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer. *Mol. Cancer* **2023**, *22*, 8. [[CrossRef](#)]
78. Zhang, X.H.; Wang, W.; Chen, X. Selection and identification of an ssDNA aptamer to NB4 cell. *J. Clin. Lab. Anal.* **2021**, *35*, e23718. [[CrossRef](#)]
79. Gao, X.; Teng, X.; Dai, Y.; Li, J. Rolling Circle Amplification-Assisted Flow Cytometry Approach for Simultaneous Profiling of Exosomal Surface Proteins. *ACS Sens.* **2021**, *6*, 3611–3620. [[CrossRef](#)]
80. Zhou, Q.; Liu, Y.; Shin, D.S.; Silangcruz, J.; Tuleuova, N.; Revzin, A. Aptamer-containing surfaces for selective capture of CD4 expressing cells. *Langmuir* **2012**, *28*, 12544–12549. [[CrossRef](#)]
81. Cheng, E.L.; Kacherovsky, N.; Pun, S.H. Aptamer-Based Traceless Multiplexed Cell Isolation Systems. *ACS Appl. Mater. Interfaces* **2022**, *14*, 44136–44146. [[CrossRef](#)]
82. Song, Z.; Mao, J.; Barrero, R.A.; Wang, P.; Zhang, F.; Wang, T. Development of a CD63 Aptamer for Efficient Cancer Immunochemistry and Immunoaffinity-Based Exosome Isolation. *Molecules* **2020**, *25*, 5585. [[CrossRef](#)] [[PubMed](#)]
83. Zhou, J.; Satheesan, S.; Li, H.; Weinberg, M.S.; Morris, K.V.; Burnett, J.C.; Rossi, J.J. Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity. *Chem. Biol.* **2015**, *22*, 379–390. [[CrossRef](#)] [[PubMed](#)]
84. Lopes-Nunes, J.; Lifante, J.; Shen, Y.; Ximendes, E.C.; Jaque, D.; Iglesias-de la Cruz, M.C.; Cruz, C. Biological studies of an ICG-tagged aptamer as drug delivery system for malignant melanoma. *Eur. J. Pharm. Biopharm.* **2020**, *154*, 228–235. [[CrossRef](#)]
85. Zhong, Y.; Zhao, J.; Li, J.; Liao, X.; Chen, F. Advances of aptamers screened by Cell-SELEX in selection procedure, cancer diagnostics and therapeutics. *Anal. Biochem.* **2020**, *598*, 113620. [[CrossRef](#)]
86. Wang, C.W.; Chung, W.H.; Cheng, Y.F.; Ying, N.W.; Peck, K.; Chen, Y.T.; Hung, S.I. A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders. *J. Allergy Clin. Immunol.* **2013**, *132*, 713–722. [[CrossRef](#)]
87. Ott, L.E.; Carson, S. Immunological tools: Engaging students in the use and analysis of flow cytometry and enzyme-linked immunosorbent assay (ELISA). *Biochem. Mol. Biol. Educ.* **2014**, *42*, 382–397. [[CrossRef](#)] [[PubMed](#)]
88. Bognár, Z.; Gyurcsányi, R.E. Aptamers against Immunoglobulins: Design, Selection and Bioanalytical Applications. *Int. J. Mol. Sci.* **2020**, *21*, 5748. [[CrossRef](#)]
89. Camorani, S.; Passariello, M.; Agnello, L.; Esposito, S.; Collina, F.; Cantile, M.; Di Bonito, M.; Ulasov, I.V.; Fedele, M.; Zannetti, A.; et al. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer. *J. Exp. Clin. Cancer Res.* **2020**, *39*, 180. [[CrossRef](#)]
90. Pastor, F.; Berraondo, P.; Etcheberria, I.; Frederick, J.; Sahin, U.; Gilboa, E.; Melero, I. An RNA toolbox for cancer immunotherapy. *Nat. Rev. Drug Discov.* **2018**, *17*, 751–767. [[CrossRef](#)]
91. Liu, C.G.; Wang, Y.; Liu, P.; Yao, Q.L.; Zhou, Y.Y.; Li, C.F.; Zhao, Q.; Liu, G.H.; Zhang, X.L. Aptamer-T Cell Targeted Therapy for Tumor Treatment Using Sugar Metabolism and Click Chemistry. *ACS Chem. Biol.* **2020**, *15*, 1554–1565. [[CrossRef](#)] [[PubMed](#)]
92. Lai, X.; Yao, F.; An, Y.; Li, X.; Yang, X. Novel Nanotherapeutics for Cancer Immunotherapy by PD-L1-Aptamer-Functionalized and Fexofenadine-Loaded Albumin Nanoparticles. *Molecules* **2023**, *11*, 2556. [[CrossRef](#)]
93. Zhang, J.; Li, W.; Qi, Y.; Wang, G.; Li, L.; Jin, Z.; Tian, J.; Du, Y. PD-L1 Aptamer-Functionalized Metal-Organic Framework Nanoparticles for Robust Photo-Immunotherapy against Cancer with Enhanced Safety. *Angew. Chem. Int. Ed. Engl.* **2023**, *26*, e202214750. [[CrossRef](#)]
94. Zhang, Y.; Xie, X.; Yeganeh, P.N.; Lee, D.J.; Valle-Garcia, D.; Meza-Sosa, K.F.; Junqueira, C.; Su, J.; Luo, H.R.; Hide, W.; et al. Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown. *Proc. Natl. Acad. Sci. USA* **2021**, *118*, e2022830118. [[CrossRef](#)]
95. Shigdar, S.; Schrand, B.; Giangrande, P.H.; de Franciscis, V. Aptamers: Cutting edge of cancer therapies. *Mol. Ther.* **2021**, *29*, 2396–2411. [[CrossRef](#)] [[PubMed](#)]
96. Camorani, S.; Granata, I.; Collina, F.; Leonetti, F.; Cantile, M.; Botti, G.; Fedele, M.; Guarracino, M.R.; Cerchia, L. Novel Aptamers Selected on Living Cells for Specific Recognition of Triple-Negative Breast Cancer. *iScience* **2020**, *23*, 100979. [[CrossRef](#)] [[PubMed](#)]
97. Wei, J.; Marisetty, A.; Schrand, B.; Gabrusiewicz, K.; Hashimoto, Y.; Ott, M.; Grami, Z.; Kong, L.Y.; Ling, X.; Caruso, H.; et al. Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. *J. Clin. Investig.* **2019**, *129*, 137–149. [[CrossRef](#)]
98. Song, W.; Li, H.; Liu, H.; Wu, Z.; Qiang, W.; Xu, D. Fabrication of streptavidin functionalized silver nanoparticle decorated graphene and its application in disposable electrochemical sensor for immunoglobulin E. *Electrochem. Commun.* **2013**, *31*, 16–19. [[CrossRef](#)]
99. Li, H.; Wang, C.; Wu, Z.; Lu, L.; Qiu, L.; Zhou, H.; Shen, G.; Yu, R. An electronic channel switching-based aptasensor for ultrasensitive protein detection. *Anal. Chim. Acta* **2013**, *758*, 130–137. [[CrossRef](#)]

100. Maehashi, K.; Matsumoto, K.; Takamura, Y.; Tamiya, E. Aptamer-Based Label-Free Immunosensors Using Carbon Nanotube Field-Effect Transistors. *Electroanalysis* **2009**, *21*, 1285–1290. [[CrossRef](#)]
101. Kim, Y.H.; Kim, J.P.; Han, S.J.; Sim, S.J. Aptamer biosensor for label-free detection of human immunoglobulin E based on surface plasmon resonance. *Sens. Actuators B: Chem.* **2009**, *139*, 471–475. [[CrossRef](#)]
102. Liu, Y.-M.; Yang, J.-J.; Cao, J.-T.; Zhang, J.-J.; Chen, Y.-H.; Ren, S.-W. An electrochemiluminescence aptasensor based on CdSe/ZnS functionalized MoS₂ and enzymatic biocatalytic precipitation for sensitive detection of immunoglobulin E. *Sens. Actuators B: Chem.* **2016**, *232*, 538–544. [[CrossRef](#)]
103. Momeni, M.; Mashayekhi, K.; Navashenaq, J.G.; Sankian, M. Identification of G-quadruplex anti-Interleukin-2 aptamer with high specificity through SELEX stringency. *Heliyon* **2022**, *8*, e09721. [[CrossRef](#)] [[PubMed](#)]
104. Du, J.; Yuan, C.; Wang, W.; Yu, Z.; Hao, R.; Zhang, Y.; Guan, M.; Li, N.; Yang, H. Aptasensor-enabled quantitative analysis of nano-sized extracellular vesicles by flow cytometry. *Analyst* **2020**, *145*, 7551–7558. [[CrossRef](#)]
105. Phung, N.L.; Walter, J.G.; Jonczyk, R.; Seiler, L.K.; Scheper, T.; Blume, C. Development of an Aptamer-Based Lateral Flow Assay for the Detection of C-Reactive Protein Using Microarray Technology as a Prescreening Platform. *ACS Comb. Sci.* **2020**, *22*, 617–629. [[CrossRef](#)]
106. Tan, X.; Jia, F.; Wang, P.; Zhang, K. Nucleic acid-based drug delivery strategies. *J. Control Release* **2020**, *323*, 240–252. [[CrossRef](#)] [[PubMed](#)]
107. Bruno, J.G. Applications in Which Aptamers Are Needed or Wanted in Diagnostics and Therapeutics. *Pharmaceuticals* **2022**, *15*, 693. [[CrossRef](#)]
108. Hou, K.; Wu, Z.X.; Chen, X.Y.; Wang, J.Q.; Zhang, D.; Xiao, C.; Zhu, D.; Koya, J.B.; Wei, L.; Li, J.; et al. Microbiota in health and diseases. *Signal Transduct. Target. Ther.* **2022**, *7*, 135. [[CrossRef](#)]
109. Thursby, E.; Juge, N. Introduction to the human gut microbiota. *Biochem. J.* **2017**, *474*, 1823–1836. [[CrossRef](#)] [[PubMed](#)]
110. Yu, D.; Meng, X.; de Vos, W.M.; Wu, H.; Fang, X.; Maiti, A.K. Implications of Gut Microbiota in Complex Human Diseases. *Int. J. Mol. Sci.* **2021**, *22*, 12661. [[CrossRef](#)]
111. Pickard, J.M.; Zeng, M.Y.; Caruso, R.; Núñez, G. Gut microbiota: Role in pathogen colonization, immune responses, and inflammatory disease. *Immunol. Rev.* **2017**, *279*, 70–89. [[CrossRef](#)]
112. Khan, I.; Bai, Y.; Zha, L.; Ullah, N.; Ullah, H.; Shah, S.R.H.; Sun, H.; Zhang, C. Mechanism of the Gut Microbiota Colonization Resistance and Enteric Pathogen Infection. *Front. Cell Infect. Microbiol.* **2021**, *11*, 716299. [[CrossRef](#)]
113. Langdon, A.; Crook, N.; Dantas, G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. *Genome Med.* **2016**, *8*, 39. [[CrossRef](#)] [[PubMed](#)]
114. Czepiel, J.; Drózd, M.; Pituch, H.; Kuijper, E.J.; Perucki, W.; Mielimonka, A.; Goldman, S.; Wultrańska, D.; Garlicki, A.; Biesiada, G. Clostridium difficile infection: Review. *Eur. J. Clin. Microbiol. Infect. Dis.* **2019**, *38*, 1211–1221. [[CrossRef](#)] [[PubMed](#)]
115. Chen, J.; Zhou, J.; Peng, Y.; Xie, Y.; Xiao, Y. Aptamers: A prospective tool for infectious diseases diagnosis. *J. Clin. Lab. Anal.* **2022**, *36*, e24725. [[CrossRef](#)] [[PubMed](#)]
116. Hu, L.; Wang, L.; Lu, W.; Zhao, J.; Zhang, H.; Chen, W. Selection, Characterization and Interaction Studies of a DNA Aptamer for the Detection of *Bifidobacterium bifidum*. *Int. J. Mol. Sci.* **2017**, *18*, 883. [[CrossRef](#)]
117. Song, S.; Wang, X.; Xu, K.; Ning, L.; Yang, X. Rapid identification and quantitation of the viable cells of *Lactobacillus casei* in fermented dairy products using an aptamer-based strategy powered by a novel cell-SELEX protocol. *J. Dairy. Sci.* **2019**, *102*, 10814–10824. [[CrossRef](#)] [[PubMed](#)]
118. Xing, H.; Zhang, Y.; Krämer, M.; Kissmann, A.K.; Amann, V.; Raber, H.F.; Weil, T.; Stieger, K.R.; Knippschild, U.; Henkel, M.; et al. A Polyclonal Aptamer Library for the Specific Binding of the Gut Bacterium *Roseburia intestinalis* in Mixtures with Other Gut Microbiome Bacteria and Human Stool Samples. *Int. J. Mol. Sci.* **2022**, *23*, 7744. [[CrossRef](#)]
119. Bhardwaj, J.; Chaudhary, N.; Kim, H.; Jang, J. Subtyping of influenza A H1N1 virus using a label-free electrochemical biosensor based on the DNA aptamer targeting the stem region of HA protein. *Anal. Chim. Acta* **2019**, *1064*, 94–103. [[CrossRef](#)]
120. Bai, C.; Lu, Z.; Jiang, H.; Yang, Z.; Liu, X.; Ding, H.; Li, H.; Dong, J.; Huang, A.; Fang, T.; et al. Aptamer selection and application in multivalent binding-based electrical impedance detection of inactivated H1N1 virus. *Biosens. Bioelectron.* **2018**, *110*, 162–167. [[CrossRef](#)]
121. Chen, H.L.; Hsiao, W.H.; Lee, H.C.; Wu, S.C.; Cheng, J.W. Selection and Characterization of DNA Aptamers Targeting All Four Serotypes of Dengue Viruses. *PLoS ONE* **2015**, *10*, e0131240. [[CrossRef](#)]
122. Morais, L.M.; Chaves, T.S.; Medeiros, M.A.; Pereira, K.A.B.; Jurgilas, P.B.; Barbosa de Lima, S.M.; Missailidis, S.; Bispo de Filippis, A.M. Selection and Characterization of Single-Stranded DNA Aptamers of Diagnostic Potential against the Whole Zika Virus. *Viruses* **2022**, *14*, 1867. [[CrossRef](#)] [[PubMed](#)]
123. Afrasiabi, S.; Pourhajbagher, M.; Raoofian, R.; Tabar zad, M.; Bahador, A. Therapeutic applications of nucleic acid aptamers in microbial infections. *J. Biomed. Sci.* **2020**, *27*, 6. [[CrossRef](#)]
124. Wandtke, T.; Woźniak, J.; Kopiński, P. Aptamers in diagnostics and treatment of viral infections. *Viruses* **2015**, *7*, 751–780. [[CrossRef](#)]
125. Li, J.; Gu, J.; Zhang, H.; Liu, R.; Zhang, W.; Mohammed-Elsabagh, M.; Xia, J.; Morrison, D.; Zakaria, S.; Chang, D.; et al. A Highly Specific DNA Aptamer for RNase H2 from *Clostridium difficile*. *ACS Appl. Mater. Interfaces* **2021**, *13*, 9464–9471. [[CrossRef](#)] [[PubMed](#)]

126. Yang, M.; Peng, Z.; Ning, Y.; Chen, Y.; Zhou, Q.; Deng, L. Highly specific and cost-efficient detection of Salmonella Paratyphi A combining aptamers with single-walled carbon nanotubes. *Sensors* **2013**, *13*, 6865–6881. [[CrossRef](#)] [[PubMed](#)]
127. Amraee, M.; Oloomi, M.; Yavari, A.; Bouzari, S. DNA aptamer identification and characterization for *E. coli* O157 detection using cell based SELEX method. *Anal. Biochem.* **2017**, *536*, 36–44. [[CrossRef](#)]
128. Wu, H.; Gu, L.; Ma, X.; Tian, X.; Fan, S.; Qin, M.; Lu, J.; Lyu, M.; Wang, S. Rapid Detection of Helicobacter pylori by the Naked Eye Using DNA Aptamers. *ACS Omega* **2021**, *6*, 3771–3779. [[CrossRef](#)]
129. Guo, K.; Song, Z.; Wang, G.; Tang, C. Detecting Redox Potentials Using Porous Boron Nitride/ATP-DNA Aptamer/Methylene Blue Biosensor to Monitor Microbial Activities. *Micromachines* **2022**, *13*, 83. [[CrossRef](#)]
130. Wang, K.; Wang, M.; Ma, T.; Li, W.; Zhang, H. Review on the Selection of Aptamers and Application in Paper-Based Sensors. *Biosensors* **2022**, *13*, 39. [[CrossRef](#)]
131. Sousa, M.P.; Piloto, A.M.L.; Pereira, A.C.; Schmitt, F.C.; Fernandes, R.; Moreira, F.T.C. New Quantum-Dot-Based Fluorescent Immunosensor for Cancer Biomarker Detection. *Chemosensors* **2022**, *10*, 518. [[CrossRef](#)]
132. Pereira, A.C.; Moreira, F.T.C.; Rodrigues, L.R.; Sales, M.G.F. Paper-based aptasensor for colorimetric detection of osteopontin. *Anal. Chim. Acta* **2022**, *1198*, 339557. [[CrossRef](#)] [[PubMed](#)]
133. Razlansari, M.; Jafarinejad, S.; Rahdar, A.; Shirvaliloo, M.; Arshad, R.; Fathi-Karkan, S.; Mirinejad, S.; Sargazi, S.; Sheervalilou, R.; Ajalli, N.; et al. Development and classification of RNA aptamers for therapeutic purposes: An updated review with emphasis on cancer. *Mol. Cell Biochem.* **2023**, *478*, 1573–1598. [[CrossRef](#)] [[PubMed](#)]
134. Pereira, C.; Parolo, C.; Idili, A.; Gomis, R.R.; Rodrigues, L.; Sales, G.; Merkoçi, A. Paper-based biosensors for Cancer Diagnosis. *Trends Chem.* **2022**, *4*, 554–567. [[CrossRef](#)]
135. Sousa, A.P.; Cunha, D.M.; Franco, C.; Teixeira, C.; Gojon, F.; Baylina, P.; Fernandes, R. Which Role Plays 2-Hydroxybutyric Acid on Insulin Resistance? *Metabolites*. **2021**, *11*, 835. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.